SCHEMBL2829315

SCHEMBL2829315

Cc1cccc(NC(=O)c2ncsc2Nc2c(Cl)cccc2Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
TP53 P04637 2/20 0.51
KMT2A Q03164 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MEN1 O00255 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CHRNA7 P36544 1/20 0.46
FLT1 P17948 1/20 0.46
KDR P35968 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HTT P42858 1/20 0.46
GRM1 Q13255 5/20 0.46
KCNK3 O14649 1/20 0.46
KCNK9 Q9NPC2 1/20 0.46
NPC1 O15118 2/20 0.45
HSP90AA1 P07900 1/20 0.45
TLR9 Q9NR96 1/20 0.45
FLT3 P36888 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830965 0.83 SMN1; SMN2 (0.55) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2832748 0.82 SMN1; SMN2 (0.46) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2827700 0.81 MEN1 (0.49) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2828965 0.81 ALDH1A1 (0.46) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2826489 0.81 KMT2A (0.53) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2830018 0.81 NAMPT (0.63) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL2829990 0.80 MEN1 (0.52) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2827185 0.80 SMN1; SMN2 (0.52) LMNATP53KMT2ASMN1; SMN2MEN1
SCHEMBL2829830 0.80 SMN1; SMN2 (0.53) TP53KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL2828874 0.79 GRM4 (0.50) TP53KMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP claimed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP claimed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US claimed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO claimed
EP-1844044-B1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-07-21 EP disclosed
US-7678815-B2 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1844044-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP disclosed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160857-A1 Thiazole-4-carboxyamide derivatives GRM1, GRM2, GRIA4 LMNA 4795/4885TP53 4722/4885KMT2A 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.